Literature DB >> 4001726

Selective immunization: protection of the individual.

J A Dudgeon.   

Abstract

Selective immunization was adopted in the United Kingdom on account of doubts about the duration of vaccine-induced immunity. Selective immunization of a particular age group had already been established as an effective procedure with bacille Calmette-Guérin (BCG) vaccine, so that practical experience was available. Initially, girls aged 11-14 years were vaccinated, but the program was extended over a 14-year period to include other groups, mainly susceptible women and other at-risk individuals. Cases of congenital rubella continue to occur, although there are signs of a decline in incidence. The number of terminations of pregnancy related to rubella in any form is high. The vaccination acceptance rate for girls aged 10-14 years increased from 35% in 1972 to 85% in 1982. The low rate of measles vaccination is considered to be a major reason for continuing with the present scheme rather than changing to the American or Swedish schemes of vaccination of preschool children with combined vaccines. A new initiative to promote rubella vaccination has recently been introduced in the United Kingdom in which charitable institutions would work together with health authorities to promote immunization against rubella.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4001726     DOI: 10.1093/clinids/7.supplement_1.s185

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

1.  Say Yes to MMR: Ethical, Scientific and Practical Reasons.

Authors:  R P Singh Tomar
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.

Authors:  T Panagiotopoulos; I Antoniadou; E Valassi-Adam
Journal:  BMJ       Date:  1999-12-04

3.  Seroepidemiology, morbidity and vaccination strategies against rubella infection. Eight years experience in Oltrepò Pavese.

Authors:  C Pelissero; C Marena; F Aguzzi; M Bevilacqua; F Rebasti
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

4.  Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets.

Authors:  Anthony Nardone; Annedore Tischer; Nick Andrews; Jo Backhouse; Heidi Theeten; Nina Gatcheva; Marios Zarvou; Bohumir Kriz; Richard G Pebody; Kalman Bartha; Darina O'Flanagan; Dani Cohen; Arnis Duks; Algirdas Griskevicius; Joel Mossong; Christopher Barbara; Adrianna Pistol; Margareta Slaciková; Katarina Prosenc; Kari Johansen; Elizabeth Miller
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

5.  Policies for immunization against rubella in European countries.

Authors:  I De la Mata; P De Wals
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082

6.  The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies.

Authors:  Nkengafac Villyen Motaze; Zinhle E Mthombothi; Olatunji Adetokunboh; C Marijn Hazelbag; Enrique M Saldarriaga; Lawrence Mbuagbaw; Charles Shey Wiysonge
Journal:  Vaccines (Basel)       Date:  2021-01-25

7.  Surveillance and control of rubella in the republic of Korea from 2001 to 2009: the necessity for enhanced surveillance to monitor congenital rubella syndrome.

Authors:  Young June Choe; Sang Taek Lee; Kyung Min Song; Heeyeon Cho; Geun-Ryang Bae; Jong-Koo Lee
Journal:  Osong Public Health Res Perspect       Date:  2010-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.